You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Cobalt™ XT ICDs and CRT-Ds are enabled with BlueSync™ technology, allowing for tablet-based programming and app-based remote monitoring. These devices include an automated ATP algorithm and are compatible with a simplified heart failure risk stratification tool.Download Brochure
Meet Cobalt XT ICDs and CRT-Ds
Exclusive ATP algorithm, heart failure risk stratification, tablet-based programming and app-based remote monitoring, extended longevity, and 40 J on all shocks.
Extended longevity, 40 J energy delivery, and exclusive technology to reduce shocks.
BlueSync technology enables tablet-based programming and app-based remote monitoring.
Simplified patient triage to identify high-risk patients.
Real-world projections based on CareLink™ patient data.
Intrinsic ATP™ is the only automated and smart ventricular antitachycardia pacing (ATP) algorithm that provides individualized therapy in real time.
In a virtual modeling study, Intrinsic ATP’s termination rate was 22% higher than traditional ATP (burst) with no difference in acceleration rate.7
for each VT
If VT is redetected,
adjusts the next
BlueSync technology within Cobalt XT enables secure, wireless communication.
Tablet-based CareLink SmartSync™ device manager
Cobalt XT ICDs and CRT-Ds
MyCareLink Heart™ mobile app or MyCareLink Relay™ Home Communicator
CareLink network and the BeConnected service
TriageHF™|| is a simplified, integrated heart failure risk assessment tool that alerts clinicians to clinically relevant changes in a patient’s status that may lead to a heart failure decompensation.
Patient’s risk level is
generated by assessing8:
Risk of a HF hospitalization in the next 30 days9
HIGHHazard Ratio 10x
MEDIUMHazard Ratio 2.1x
LOWNeg Pred Value 99.4%
Discover exclusive features and algorithms available in Cobalt XT ICDs and CRT-Ds.
With AdaptivCRT™ programmed to BiV and LV.
Energy delivered at connector block into a 50 Ω ± 1% load.
Energy stored at charge end on capacitor.
From ADVANCE III, using ATP during charging along with NID = 30/40 programming, ATP reduced shocked episodes by 52%.10
TriageHF is not an alarm. The TriageHF assessment does not replace heart failure assessments in standard clinical practice. Medical treatment should not be modified remotely based solely on the TriageHF assessment. Interpretation of the TriageHF assessment requires clinical judgement by a medical professional. The TriageHF assessment should be used in conjunction with professional guidelines for patient management decisions.
Medtronic Claria MRI™ Quad CRT-D SureScan™ and Amplia MRI™ Quad CRT-D SureScan™ Median Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.
Medtronic Cobalt™ XT HF Quad MRI SureScan™ Model DTPA2QQ device manual.
Medtronic Evera MRI™ XT DR SureScan™ and Evera MRI™ S DR SureScan™ Median Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.
Medtronic Cobalt™ XT DR MRI SureScan™ Model DDPC3D4 device manual.
Medtronic Visia AF™ VR and Visia AF MRI™ VR SureScan™ Median Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.
Medtronic Cobalt™ XT VR MRI SureScan™ Model DVPC3D4 device manual
Swenson D, et al. A self-adaptive approach to antitachycardia pacing – a head to head comparison using advanced computational modeling. Poster P6555 presented at ESC Congress 2019; Amsterdam.
Medtronic CareLink™ Heart Failure Risk Status Technical Manual M945636A001 A.
Cowie MR, Sarkar S, Koehler J, et al. Development and validation of an integrated diagnostic algorithm derived from parameters monitored in implantable devices for identifying patients at risk for heart failure hospitalization in an ambulatory setting. Eur Heart J. August 2013;34(31):2472-2480.
Arenal A, Proclemer A, Kloppe A, et al. Different impact of long-detection interval and anti-tachycardia pacing in reducing unnecessary shocks: data from the ADVANCE III trial. Europace. November 2016;18(11):1719-1725.